Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Lindberg

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
The New England Journal of Medicine|November 27, 2014
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequenceGiulio Genovese, Anna K Kähler, Robert E Handsaker, et al.
European Urology|November 6, 2016
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate TumorsEmilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, et al.
Genome Medicine|November 22, 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisMarkus Mayrhofer, Bram De Laere, Tom Whitington, et al.
International Journal of Molecular Sciences|May 2, 2020
Removing Critical Gaps in Chemical Test Methods by Developing New Assays for the Identification of Thyroid Hormone System-Disrupting Chemicals-The ATHENA ProjectAndreas Kortenkamp, Marta Axelstad, Asma H Baig, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
The Lancet. Oncology|January 14, 2020
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic studyPeter Ström, Kimmo Kartasalo, Henrik Olsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2018
<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerBram De Laere, Steffi Oeyen, Markus Mayrhofer, et al.
Nature Medicine|August 28, 2024
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Nature Communications|February 28, 2024
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancerNicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The New England Journal of Medicine|November 27, 2014
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequenceGiulio Genovese, Anna K Kähler, Robert E Handsaker, et al.
European Urology|November 6, 2016
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate TumorsEmilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, et al.
Genome Medicine|November 22, 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisMarkus Mayrhofer, Bram De Laere, Tom Whitington, et al.
International Journal of Molecular Sciences|May 2, 2020
Removing Critical Gaps in Chemical Test Methods by Developing New Assays for the Identification of Thyroid Hormone System-Disrupting Chemicals-The ATHENA ProjectAndreas Kortenkamp, Marta Axelstad, Asma H Baig, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
The Lancet. Oncology|January 14, 2020
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic studyPeter Ström, Kimmo Kartasalo, Henrik Olsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2018
<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerBram De Laere, Steffi Oeyen, Markus Mayrhofer, et al.
Nature Medicine|August 28, 2024
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Nature Communications|February 28, 2024
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancerNicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 11